Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Regulatory environment for novel therapeutic development in mitochondrial diseases

Journal of Inherited Metabolic Disease(2020)10.1002/jimd.12353Source: DataRank Database

Regulatory environment for novel therapeutic development in mitochondrial diseases is a research paper published in Journal of Inherited Metabolic Disease (2020). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.16)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Andrés Berardo ORCID,Emanuele Barca ORCID,Valentina Emmanuele ORCID,Catarina M. Quinzii ORCID,Camilla V. Simpson

Live enrichment

PubMed:33368420 PMC:PMC9326497 OpenAlex:https://openalex.org/W3115808945

U.S. Department of Defense

Grant: W81XWH2010807

Muscular Dystrophy Association

Grant: 577391

National Institutes of Health

Grant: U54NS078059

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5U54NS078059-10

The North American Mitochondrial Disease Consortium (NAMDC)

FWCI

0.16

Citation Percentile

0.6%

Citation Trend

2021

2025

greenLicense: Wiley Online Library User Agreement

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9326497

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/jimd.12353

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/jimd.12353

publisherhttps://onlinelibrary.wiley.com/doi/am-pdf/10.1002/jimd.12353

Fields of Study

Genomics and Rare DiseasesHealth Systems, Economic Evaluations, Quality of LifeMetabolism and Genetic Disorders0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansOrphan Drug ProductionUnited StatesUnited States Food and Drug AdministrationDrug ApprovalMitochondrial DiseasesRare Diseases

Keywords

LegislationRegulatory scienceOrphan drugDrug developmentEuropean unionRegulatory affairsClinical trialMedicinePharmaceutical industryFlexibility (engineering)Agency (philosophy)IncentiveDiseaseIntensive care medicineBusinessDrugPharmacologyBioinformaticsPolitical sciencePathologyPublic administrationBiologyInternational tradeLawManagementTherapyFood And Drug AdministrationMitochondrial DiseaseTk2Thymidine Kinase 2Mitochondrial DiseasesRare DiseasesOrphan Drug ProductionUnited States Food and Drug AdministrationHumansDrug ApprovalUnited States

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Partnerships for the goals

Regulatory environment for novel therapeutic development in mitochondrial diseases

FAIR Checklist

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)